Skip to main content

Bruce Spiegelman Joins Cytrx Subsidiary Board; Craig Venter, Hamilton Smith, Headline New Metabolon SAB; Pernet New Quark Biotech President

NEW YORK, Dec. 10 (GenomeWeb News) - Bruce Spiegelman has been appointed to the scientific advisory board of Araios, the obesity and type 2 diabetes subsidiary of Cytrx.


Spiegelman is a professor of cell biology at Harvard Medical School and the Dana-Farber Cancer Institute, which he joined in 1991 as an assistant professor. His work uses adipogenesis as a model system to understand the molecular basis of cell differentiation and tissue development. His lab also studies adipogenesis-related metabolig diseases-in particular, obesity and insulin-resistant diabetes.


Cytrx, of Los Angeles, has programs to develop drugs using RNA interference.


René Bruno has joined Pharsight as managing director of drug development consulting services in Europe. The Mountain View, Calif. pharmaceutical IT consulting company said Bruno will oversee and expand the company's services in the European market.


Bruno comes to Pharsight from a three-years stint at Genentech, where he was most recently senior scientist and led the pharmacometry unit. He also has served as a research advisor for 13 years at Rhone-Poulenc Rorer, and as a pharmacokineticist at Syntex Research in France.


Andre Pernet has been appointed president of Quark Biotech, of Fremont, Calif., which bought Incyte's microarray business in 2002, the company said Dec. 9. Currently, he serves as chairman of CURx Pharma and is on the board of directors of Kaleidos Pharmaceuticals. Between 2000 and 2002, Pernet was Chairman and CEO of Genset. Prior to that, he served as corporate officer and vice president, pharmaceutical products research and development at Abbott Laboratories, which he joined in 1973 as a research chemist.


In recent years, Pernet has also served on the boards of Celeris, Synsorb, Advanced Pharma, and Genescape, and on the scientific board of Pathogenesis.


Craig Venter and Hamilton Smith, as well as Oliver Smithies, Flint Beal, and Donalt Kufe, have been appointed as the founding members of Metabolon's Scientific Advisory Board, the Research Triangle Park, NC metabolomics company said Monday.


Smith, who is chair of the SAB, is the scientific director of Venter's Institute of Biological Energy Alternatives. He was formerly director of DNA resources at Celera, which he joined in 1998.  A co-recipient of the 1978 Nobel Prize in Medicine for the discovery of Type II restriction enzymes, he also has collaborated with  the Institute for Genomic Research genome of H. influenza, as well as bacterial organisms.


Venter is currently president of the Center for the Advancement of Genomics, the Center for the Advancement of Genomics; the IBEA; and the Craig Venter Science Foundation. He is also the former president of Celera, where he led the company's efforts to sequence the human genome and the founder and is chairman of TIGR, in Rockville, Md.


Schimmel is a professor at the Scripps Research Institute. He is a co-founder of the companies Alkermes, Cubist, Repligen, and Alnylam, and was formerly a professor of biochemistry and biophysics at the MIT department of biology.


Smithies is a professor of pathology and laboratory medicine at the University of North Carolina at Chapel Hill.  Prior to that, he was a professor at the University of Wisconsin and is known for his work in targeted homologous recombination in transgenic mice. 

Beal is the chairman of the department of neurology and neuroscience at the Cornell Weill Medical College and is director of the neurology service at the New York Presbyterian Cornell Campus.  Prior to joining Cornell, he was professor of neurology at the Harvard Medical School and Chief of the neurochemistry laboratory at Massachusetts General Hospital.


Kufe is chief of cancer pharmacology in the department of adult oncology at the Dana-Farber Cancer Institute, and is a professor of medicine at Harvard Medical School. His research has focused on the MUC1 antigen, which has been the basis for breast cancer vaccine clinical trials.

The Scan

US Supports Patent Waivers

NPR reports that the Biden Administration has announced its support for waiving intellectual property protections for SARS-CoV-2 vaccines.

Vaccines Versus Variants

Two studies find the Pfizer-BioNTech SARS-CoV-2 vaccine to be effective against viral variants, and Moderna reports on booster shots to combat variants.

CRISPR for What Ails You

The Wall Street Journal writes that CRISPR-based therapies could someday be used to treat common conditions like heart attacks.

Nature Papers Review Integration of Single-Cell Assay Data, Present Approach to Detect Rare Variants

In Nature this week: review of ways to integrate data from single-cell assays, and more.